Forma wins $20M payout in Eisai pact

Eisai will tap into Forma Therapeutics' compound library and cell-based screening platforms under a discovery pact that will pay Forma $20 million in an upfront and committed funding over a three-year period. "Forma's unique drug discovery capabilities will enable Eisai to access diversified chemistry and drug discovery technologies to identify novel drug candidates for otherwise difficult targets," said Kentaro Yoshimatsu, CSO for Eisai Product Creation Systems. Eisai release

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.